[Home] [Bipolar News] [Bipolar Disorder] [Medications] [Treatments] [BP/Job/School] [Disability] [Ask the Doctor] [Ask David] [Self-Injury] [Personal Stories] [Graham's Column] [Steven's Column] [Storm's Column] [Columnist Archives] [Suicide] [Community Support] [Family Members] [Expressions] [Greeting Cards] [Books] [Awards] [Links & Rings] [About Us] [Contact Us]
FDA Approved Drugs » 2012
Medical Areas: Endocrinology | Family Medicine
View By:Year | Company | Conditions | Therapeutic Areas | Drug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Corcept Therapeutics
Approval Status: Approved February 2012
Treatment Area: hyperglycemia in adults with endogenous Cushing’s syndrome
Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
Korlym was specifically approved to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type II diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Korlym is supplied as a tablet for oral administration. The recommended initial dose is a single dose of 300 mg orally once daily. The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks.
FDA ApprovalThe FDA approval of Korlym was based on an uncontrolled, open-label, 24-week, multicenter clinical study. The study enrolled 50 subjects with clinical and biochemical evidence of hypercortisolemia despite prior surgical treatment and radiotherapy. The subjects were placed in one of two cohorts: a diabetes cohort and a hypertension cohort and were evaluated separately. Korlym treatment was started at a dose of 300 mg once a day. The study protocol allowed an increase in dose to 600 mg after two weeks, and then by additional 300 mg increments every four weeks to a maximum of 900 mg per day for patients <60 kg, or 1200 mg per day for patients >60 kg.Diabetes CohortThe primary efficacy analysis for the diabetes cohort was an analysis of responders. A responder was defined as a subject who had a ≥25% reduction from baseline in glucose AUC. Fifteen of 25 subjects (60%) were treatment responders.Hypertension CohortThere were no changes in mean systolic and diastolic blood pressures at the end of the trial relative to baseline.
Adverse events associated with the use of Korlym may include, but are not limited to, the following:
Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
For additional information regarding Korlym or hyperglycemia in adults with endogenous Cushing’s syndrome, please visit the Corcept web page.
� 1998, 1999, 2000, 2001,
2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010
Owners: Allie Bloom, David Schafer, M.Ed. (Blackdog)
John Haeckel, Judith (Duff)
Founder: Colleen Sullivan
Email Us at
Add a Link
Ask the Doctor
Dr. Plyler about Bipolar Disorder
Ask The Doctor/Topic Archives
Benny the Bipolar Puppy
Bipolar Disorder News
Bipolar Help Contract
Bipolar World Forums
& Other mental Illness
Clinical Research Trials & FDA Drug Approval
The Continuum of Mania and Depression
Criteria and Diagnosis Criteria-World
Expressions (Poetry, Inspiration, Humor, Art Gallery,
Getting Help for a Loved One who Refuses Treatment
Greeting Cards History
of Mental Illness
Job and School Links
Medication and Weight Gain
News of the Day
Pay for Meds Personal
Stigma and Mental Health Law
The Suicide Wall
Table of Contents
US Disability Veteran's